Effects of coadministration of natural polyphenols with doxycycline or calcium modulators on acute Chlamydia pneumoniae infection in vitro

Journal of Antibiotics

Volumn 64, Issue 11, 2011, Pages 747-752

  Salin, Olli P ^a   Pohjala, Leena L ^a   Saikku, Pekka ^b   Vuorela, Heikki J ^c   Leinonen, Maija ^d   Vuorela, Pia M ^a  

^a ÅBO AKADEMI UNIVERSITY   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Antimicrobial effect; Chlamydia; Phenolic compound; Synergy

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DOXYCYCLINE; GALLIC ACID; GALLIC ACID OCTYL ESTER; ISRADIPINE; LUTEOLIN; POLYPHENOL DERIVATIVE; QUERCETIN; RHAMNETIN; THAPSIGARGIN; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; BACTERIAL GROWTH; CELL VIABILITY; CHLAMYDIAL PNEUMONIA; CONTROLLED STUDY; DRUG INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; LUNG ALVEOLUS EPITHELIUM; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; CALCIUM; CELL LINE; CELL SURVIVAL; CHLAMYDOPHILA PNEUMONIAE; DOXYCYCLINE; DRUG SYNERGISM; EPITHELIAL CELLS; HUMANS; POLYPHENOLS;

EID: 82355175639     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2011.79     Document Type: Article

References (33)

1. Kuo, C. C., Jackson, L. A., Campbell, L. A. & Grayston, J. T. Chlamydia pneumoniae. Clin. Microbiol. Rev. 8, 451-461 (1995).
2. Rassu,M. et al. Demonstration of Chlamydia pneumoniae in atherosclerotic arteries from various vascular regions. Atheroscerosis 158, 73-79 (2001). (Pubitemid 32735469)
3. Cao, F., Castrillo, A., Tontonoz Re, F. & Byrne, G. I. Chlamydia pneumoniae-induced macrophage foam cell formation is mediated by Toll-like receptor 2. Infect. Immun. 75, 753-759 (2007). (Pubitemid 46203437)
4. Blessing, E., Campbell, L. A., Rosenfeld, M. E., Chough, N. & Kuo, C. C. Chlamydia pneumoniae infection accelerates hyperlipidemia induced atherosclerotic lesion development in C57BL/6J mice. Atherosclerosis 158, 13-17 (2001). (Pubitemid 32735462)
5. Volanen, I. et al. Increased aortic intima-media thickness in 11-year-old healthy children with persistent Chlamydia pneumoniae seropositivity. Arterioscler. Thromb. Vasc. Biol. 26, 649-655 (2006).
6. Kohanski, M., Dwyer, D. & Collins, J. J. How antibiotics kill bacteria: From targets to networks. Nat. Rev. Microbiol. 8, 423-435 (2010).
7. Carter, J. D. et al. Combination antibiotics as a treatment for chronic Chlamydiainduced reactive arthritis. Arthritis. Rheum. 62, 1298-1307 (2010).
8. Kutlin, A., Roblein, P. M. & Hammerschlag, M. R. Effect of prolonged treatment with azithromycin, clarithromycin or levofloxacin on Chlamydia pneumoniae in a continuousinfection model.. Antimicrob. Agents Chemother. 46, 409-412 (2002). (Pubitemid 34087188)
9. Grayston, J. T. Infections caused by Chlamydia pneumoniae strain TWAR. Clin. Infect. Dis. 15, 757-763 (1992).
10. Gieffers, G., Rupp, J., Gebert, A., Solbach, W. & Klinger, M. First-choice antibiotics at subinhibitory concentrations induce persistence of Chlamydia pneumoniae.. Antimicrob. Agents Chemother. 48, 1402-1405 (2004). (Pubitemid 38405505)
11. Bellman-Weiler, R. et al. Divergent modulation of Chlamydia pneumoniae infection cycle in human monocytic and endothelial cells by iron, tryptophan availability and interferon gamma. Immunobiology 215, 842-848 (2010).
12. Gieffers, G. et al. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation. 103, 351-356 (2001).
13. Mazumdar, K., Kumar, K. A. & Dutta, N. K. Potential role of the cardiovascular nonantibiotic (helper compound) amlodipine in the treatment of microbial infections: Scope and hope for the future. Int. J. Antimicrob. Agents 36, 295-302 (2010).
14. Shainkin-Kestenbaum, R., Winikoff, Y., Kol, R., Chaimovizt, C. & Sarov, I. Inhibition of growth of Chlamydia trachomatis by the calcium antagonist verapamil. J. Gen. Microbiol. 135, 1619-1623 (1989). (Pubitemid 19168957)
15. Azenabor, A. A. & Chaudhry, A. U. Macrophage L-type Ca2+ channel antagonists alter Chlamydia pneumoniae MOMP and HSP-60 mRNA gene expression, and improve antibiotic susceptibility. Immunobiology 207, 237-245 (2003). (Pubitemid 37009920)
16. Azenabor, A. A. Treatment of chronic bacterial infections Pat. Pub. No: WO 2005/ 007082. International Application No.: PCT/US2004/016780.
17. Alvesalo, J., Vuorela, H., Tammela, P., Leinonen, M., Saikku, P. & Vuorela, P. Inhibitory effect of dietary phenolic compounds on Chlamydia pneumoniae in cell cultures. Biochem. Pharmacol. 71, 735-741 (2006). (Pubitemid 43208829)
18. Törmäkangas, L. et al. In vivo treatment of acute Chlamydia pneumoniae infection with the flavonoids quercetin and luteolin and an alkyl gallate, octyl gallate, in a mouse model. Biochem. Pharmacol. 70, 1222-1230 (2005). (Pubitemid 41317516)
19. Scholz, E. P., Zitron, E., Katus, H. A. & Carle, C. A. Cardiovascular ion channels as a molecular target of flavonoids. Cardiovasc. Ther. 28, 46-52 (2010).
20. Summanen, J. et al. Effects of simple aromatic compounds and flavonoids on Ca2+ fluxes in rat pituitary GH4C1 cells. Eur. J. Pharmacol. 414, 125-133 (2001). (Pubitemid 32181879)
21. Cushnie, T. P. T. & Lamb, A. G. Antimicrobial activity of flavonoids. Int. J. Antimicrob. Agents 26, 343-356 (2005). (Pubitemid 41483464)
22. Gibbons, S. Plants as a source of bacterial resistance modulators and anti-infective agents. Phytochem. Rev. 4, 63-78 (2005). (Pubitemid 41187760)
23. Lewis, K. & Ausubel, F. M. Prospects for plant-derived antibacterial. Nat. Biotechnol. 24, 1504-1507 (2006).
24. Jayaraman, P., Sakharkar, M. K., Lim, C. S., Tang, T. H. & Sakharkar, K. R. Activity and interactions of antibiotic and phytochemical combinations against Pseudomonas aeruginosa in vitro. Int. J. Biol. Sci. 6, 556-568 (2010).
25. Liebermann, L. A. & Higgins, D. E. Inhibition of Listeria monocytogenes infection by neurological drugs. Int. J. Antimicrob. Agents 35, 292-296 (2010).
26. Gunics, G., Motohasi, N., Amaral, L., Farkas, S. & Molná r, J. Interaction between antibiotics and non-conventional antibiotics on bacteria. Int. J. Antimicrob. Agents 14, 239-242 (2000). (Pubitemid 30201551)
27. Azenabor, A. & Chaudry, A. Effective macrophage redox defence against Chlamydia pneumoniae depends on L-type Ca2+ channel activation. Med. Microbiol. Immunol. 192, 99-106 (2003). (Pubitemid 36714126)
28. Majeed, M., Krause, K.- H., Clark, R., Kihlström, E. & Stendahl, O. Localization of intracellular Ca2+ stores in HeLa cells during infection with Chlamydia trachomatis. J. Cell Sci. 112, 35-44 (1999). (Pubitemid 29043833)
29. Majeed, M., Ernst, J., Magnusson, K.- E., Kihlström, E. & Stendahl, O. Selective translocation of annexins during intracellular redistribution of Chlamydia trachomatis in HeLa and McCoy cells. Infect. Immun. 62, 126-134 (1994). (Pubitemid 24011950)
30. Alvesalo, J. et al. Microarray analysis of a Chlamydia pneumoniae-infected human epithelial cell line by use of gene ontology hierarchy. J. Infect. Dis. 197, 156-162 (2008). (Pubitemid 351263480)
31. Salin, O. et al. Inhibitory effect of the natural product betulin and its derivatives against the intracellular bacterium Chlamydia pneumoniae. Biochem. Pharmacol. 80, 1141-1151 (2010).
32. Keurulainen, L. et al. Design and synthesis of 2-arylbenzimidazoles and evaluation of their inhibitory effect against Chlamydia pneumoniae. J. Med. Chem. 53, 7664-7674 (2010).
33. How, S. J., Hobson, D., Hart, A. C. & Webster, R. E. An in vitro investigation of synergy and antagonism between antimicrobials against Chlamydia trachomatis. J. Antimicrob. Chemother. 15, 533-538 (1985). (Pubitemid 15093193)